Table 2 Patient eligibility criteria.

From: Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design

Patient eligibility criteria

 Providing written informed consent for participation in the study

 Having NVAF treated with edoxaban

 Undergone successful PCI

 Having no planned elective cardiac intervention for the entire study duration (up to 1 year)

 Capability, availability, and willingness for follow-up by telephone by the site for the entire study duration (up to 1 year)

 No simultaneous participation in any other interventional study

 ≥ 18 years of age

 Life expectancy > 1 year

  1. NVAF non-valvular atrial fibrillation, PCI percutaneous coronary intervention.
Back to article page